VEGFA and retinopathy of prematurity: The discovery that MGC is the primary source of VEGF-A release in the neuroretina has sparked an interest in investigating whether therapies targeting these cells could help halt or limit the progression of vasoproliferative diseases, such as proliferative diabetic retinopathy (PDR), retinopathy of prematurity (ROP), and age-related macular degeneration (AMD).